A neutralizing antibody prevents postfusion transition of measles virus fusion protein.

Autor: Zyla DS; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Della Marca R; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli,' 81100 Caserta, Italy., Niemeyer G; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Luebeck, D-23538 Luebeck, Germany., Zipursky G; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Stearns K; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Leedale C; Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA., Sobolik EB; Department of Laboratory Medicine and Pathology Virology Division, University of Washington, Seattle, WA 98109, USA., Callaway HM; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Hariharan C; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Peng W; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CH Utrecht, Netherlands.; Netherlands Proteomics Center, 3584 CH Utrecht, Netherlands., Parekh D; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Marcink TC; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Diaz Avalos R; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Horvat B; Immunobiology of Viral Infections, International Center for Infectiology Research-CIRI, INSERM U1111, CNRS UMR5308, University Lyon 1, ENS de Lyon, 69007 Lyon, France., Mathieu C; Centre International de Recherche en Infectiologie équipe Neuro-Invasion, TROpism and VIRal Encephalitis (NITROVIRE), INSERM U1111-Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, 69007 Lyon, France., Snijder J; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CH Utrecht, Netherlands.; Netherlands Proteomics Center, 3584 CH Utrecht, Netherlands., Greninger AL; Department of Laboratory Medicine and Pathology Virology Division, University of Washington, Seattle, WA 98109, USA., Hastie KM; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., Niewiesk S; Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA., Moscona A; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA., Porotto M; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli,' 81100 Caserta, Italy., Ollmann Saphire E; Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Jazyk: angličtina
Zdroj: Science (New York, N.Y.) [Science] 2024 Jun 28; Vol. 384 (6703), pp. eadm8693. Date of Electronic Publication: 2024 Jun 28.
DOI: 10.1126/science.adm8693
Abstrakt: Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in the general population declines and as populations of immunocompromised individuals, who cannot be vaccinated, increase. There are no approved therapeutics for MeV. Neutralizing antibodies targeting viral fusion are one potential therapeutic approach but have not yet been structurally characterized or advanced to clinical use. We present cryo-electron microscopy (cryo-EM) structures of prefusion F alone [2.1-angstrom (Å) resolution], F complexed with a fusion-inhibitory peptide (2.3-Å resolution), F complexed with the neutralizing and protective monoclonal antibody (mAb) 77 (2.6-Å resolution), and an additional structure of postfusion F (2.7-Å resolution). In vitro assays and examination of additional EM classes show that mAb 77 binds prefusion F, arrests F in an intermediate state, and prevents transition to the postfusion conformation. These structures shed light on antibody-mediated neutralization that involves arrest of fusion proteins in an intermediate state.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje